74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Regulus Therapeutics Inc
Closed
1.31 3.97
Overview
Share price change
24h
Min
1.31
Max
1.33
Income | -3M -14M |
|---|---|
EPS | -0.21 |
Employees | 32 |
EBITDA | -3.1M -14M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +510.69 upside |
Next Earnings | 19 Mar 2025 |
|---|
Market Cap | 85M |
|---|---|
Previous open | -2.66 |
Previous close | 1.31 |
Regulus Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Regulus Therapeutics Inc Forecast
Price Target
By TipRanks
510.69% upside
12 Months Forecast
Average 8 USD 510.69%
High 8 USD
Low 8 USD
Based on 2 Wall Street analysts offering 12 month price targets forRegulus Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Regulus Therapeutics Inc
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
